ClinicalTrials.gg
TerminatedNCT06288282Updated Oct 13, 2026

Behavioral and Cognitive Predictors of Persistent Pain and Opioid Misuse in Chronic Pain

An observational study in Chronic Back Pain, sponsored by Icahn School of Medicine at Mount Sinai. Terminated at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Icahn School of Medicine at Mount Sinai · Observational

How we know

Why this study was terminated
PI leaving institution
Updated Oct 13, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
130
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 307 studies in Back Pain with a site in United States — 38 open to participants now, 51 under way, 4 of them phase 3. Back Pain · United States.

Enrollment
23rd of 44
130 · median 133
Started
2023
with 13 others
Observational
44 of 307
7 open now
Registered
272nd of 307
by date

Among the 307 studies in Back Pain with a site in United States, this one is the 23rd largest by enrollment of the 44 observational ones that give a count, is one of 14 that started in 2023, is one of 44 observational ones, and was the 272nd registered.

Back Pain

729 studies on the registry are indexed under Back Pain; 110 are open to participants now.

Browse Back Pain studies →

Open to participants now

38 of the 307 studies in Back Pain with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 68 Back Pain studies recruiting now, 29 (43%) set no upper age limit and 32 (47%) stop at 75 or younger; 3 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 307 studies in Back Pain with a site in United States, or all of them as a file.
02

Study summary

Chronic lower back pain (CLBP) affects approximately 20% of the global population. The study objective is to determine if impulsivity, inhibitory control, drug choice, and/or cognitive distortions predict opioid misuse and disability in patients with chronic pain. This is a prospective consented cross-sectional study characterizing behavioral and cognitive phenotypes using both patient-reported survey measures and cognitive testing. Outcome measures include correlations between impulsivity measures, opioid drug choice responses and cognitive distortion scores, and risk for opioid misuse (Primary outcomes: COMM scores, SOAPPR scores). Secondary outcomes is BPI measurement. A Certificate of Confidentiality will provide additional protections for participants.

03

Conditions studied

  • Chronic Back Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

chronic back pain

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • With diagnoses related to chronic lower back pain
  • Age above 18yrs
  • Non pregnant

Exclusion criteria

Exclusion Criteria:

  • Cancer pain
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
130 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Patients with chronic back pain with lumbar, cervical or thoracic spine diagnoses.

    Other: No Intervention

Interventions

  • OtherNo Intervention

    No intervention will be used.

06

What researchers measure

Primary outcomes

  1. Screener and Opioid Assessment for patients with pain revised (SOAPPR)

    Risk of opioid misuse with the Screener and Opioid Assessment for Patients with Pain Revised (SOAPPR). The Screener and Opioid Assessment for Patients with Pain-Revised (SOAPP-R) is a 24-item self-report questionnaire with total scores ranging from 0 to 24 that is used to predict risk of aberrant medication-related behaviors among chronic pain patients, with higher scores indicating higher risk of aberrant behaviors.

    Time frame: within 12 months

  2. Current Opioid misuse measure (COMM) surveys

    Current opioid misuse measures with the Current Opioid misuse measure (COMM) surveys. The COMM is a 17-item self-report measure with total scores ranging from 0 to 68 that is used to identify risk of opioid misuse among chronic pain patients, with higher scores indicating higher risk of opioid misuse.

    Time frame: within 12 months

Secondary outcomes

  1. Pain Intensity with Brief Pain inventory (BPI)

    The Brief Pain Inventory (BPI) pain intensity scale is a 0 to 10 numeric rating scale used to assess a patient's pain intensity, with 0 being no pain and 10 being pain as bad as you can imagine. Higher scores indicate higher pain intensity.

    Time frame: within 12 months

07

Study locations

1 site
  • Mount Sinai Pain management centers
    New York, New York 10029, United States
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).

Supporting information: Statistical analysis plan, Clinical study report

Time frame: Immediately following publication. No end date.

Access criteria: Investigators whose proposed use of the data has been approved by an independent review committee ('learned intermediary') identified for this purpose. For individual participant data meta-analysis. Proposals should be directed to chinwe.nwaneshiudu@mountsinai.org. To gain access, data requestors will need to sign a data access agreement. Data are available for 5 years at a third-party website (TBD)

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Dec 2023 to primary completion in Aug 2026, 32 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Dec 2025 → Aug 2026 and completion Dec 2025 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2024
First posted
Mar 1, 2024
StartActual
Dec 20, 2023
Primary completionActual
Aug 31, 2026was Dec 2025
CompletionActual
Aug 31, 2026was Dec 2025
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated PI leaving institution
changed Oct 13, 2026
Primary completion
Dec 2025→Aug 31, 2026 (actual)
Oct 13, 2026
Study completion
Dec 2025→Aug 31, 2026 (actual)
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Recruiting→Terminated
    Why stopped PI leaving institution
    Primary completion Dec 2025→Aug 31, 2026 (now actual)
    Study completion Dec 2025→Aug 31, 2026 (now actual)
    + 4 other changes: verification date, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06288282
Responsible party
Chinwe Nwaneshiudu (Assistant Professor, Icahn School of Medicine at Mount Sinai) — Principal investigator
First posted
Mar 1, 2024
Start date
Dec 20, 2023
Primary completion
Aug 31, 2026
Completion
Aug 31, 2026
Last update
Oct 13, 2026

Study contacts

Chinwe Nwaneshiudu
principal investigator · Icahn School of Medicine at Mount Sinai

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion